Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

doi:10.1016/j.jhep.2020.09.024

科研成果详情

题名	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study
作者	Marjot, Thomas 1; Moon, Andrew M.2; Cook, Jonathan A.3; Abd-Elsalam, Sherief 4; Aloman, Costica 5; Armstrong, Matthew J.6; Pose, Elisa 7,8; Brenner, Erica J.9; Cargill, Tamsin 1; Catana, Maria-Andreea 10; Dhanasekaran, Renumathy 11; Eshraghian, Ahad 12; García-Juárez, Ignacio 13; Gill, Upkar S.14; Jones, Patricia D.15; Kennedy, James 1; Marshall, Aileen 16; Matthews, Charmaine 17; Mells, George 18; Mercer, Carolyn 1; Perumalswami, Ponni V.19; Avitabile, Emma 7; Qi, Xialong 20; Su, Feng 21; Ufere, Nneka N.22; Wong, Yu Jun 23; Zheng, Ming-Hua24,25; Barnes, Eleanor 1; Barritt, Alfred S.2; Webb, Gwilym J.1,18
发表日期	2021-03
发表期刊	JOURNAL OF HEPATOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	SARS-CoV-2 COVID-19 Chronic liver disease Cirrhosis Acute-on-chronic liver failure
其他关键词	ALCOHOL-USE ; CIRRHOSIS ; COVID-19 ; MORTALITY
摘要	Background & Aims: Chronic liver disease (CLD) and cirrhosis are associated with immune dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes following SARS-CoV-2 infection. We aimed to determine the impact of COVID-19 on patients with pre-existing liver disease, which currently remains ill-defined. Methods: Between 25th March and 8th July 2020, data on 745 patients with CLD and SARS-CoV-2 (including 386 with and 359 without cirrhosis) were collected by 2 international registries and compared to data on non-CLD patients with SARS-CoV-2 from a UK hospital network. Results: Mortality was 32% in patients with cirrhosis compared to 8% in those without (p < 0.001). Mortality in patients with cirrhosis increased according to Child-Pugh class (A [19%], B [35%], C [51%]) and the main cause of death was from respiratory failure (71%). After adjusting for baseline characteristics, factors associated with death in the total CLD cohort were age (odds ratio [OR] 1.02; 1.01-1.04), Child-Pugh A (OR 1.90; 1.03-3.52), B (OR 4.14; 2.4-7.65), or C (OR 9.32; 4.80-18.08) cirrhosis and alcohol-related liver disease (OR 1.79; 1.03-3.13). Compared to patients without CLD (n = 620), propensity-score-matched analysis revealed significant increases in mortality in those with Child-Pugh B (+20.0% [8.8%-31.3%]) and C (+38.1% [27.1%- 49.2%]) cirrhosis. Acute hepatic decompensation occurred in 46% of patients with cirrhosis, of whom 21% had no respiratory symptoms. Half of those with hepatic decompensation had acute-on-chronic liver failure. Conclusions: In the largest such cohort to date, we demonstrate that baseline liver disease stage and alcohol-related liver disease are independent risk factors for death from COVID-19. These data have important implications for the risk stratification of patients with CLD across the globe during the COVID-19 pandemic. Lay summary: This international registry study demonstrates that patients with cirrhosis are at increased risk of death from COVID-19. Mortality from COVID-19 was particularly high among patients with more advanced cirrhosis and those with alcohol-related liver disease. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.
资助项目	European Association for the Study of the Liver (EASL) [2020RG03]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DK007634, UL1TR002489]; North Carolina Translational and Clinical Sciences Institute (CTSA) [UL1TR002489]; NIHRNational Institute for Health Research (NIHR); WT training fellowship for clinicians [211042/Z/18/Z]; Oxford NIHR Biomedical Research CentreNational Institute for Health Research (NIHR)
出版者	ELSEVIER
出版地	AMSTERDAM
ISSN	0168-8278
EISSN	1600-0641
卷号	74 期号:3 页码:567-577
DOI	10.1016/j.jhep.2020.09.024
页数	11
WOS类目	Gastroenterology & Hepatology
WOS研究方向	Gastroenterology & Hepatology
WOS记录号	WOS:000620497200012
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	33035628
PMC记录号	PMC7536538
SCOPUSEID	2-s2.0-85094681277
ESI热点论文	2021-07 ; 2021-09 ; 2021-11 ; 2023-03
ESI高被引论文	2021-07 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05 ; 2024-07 ; 2024-09 ; 2024-11 ; 2025-01
自科自定义期刊分类	T2(B)类
通讯作者地址	[Marjot, Thomas]Oxford Liver Unit,Translational Gastroenterology Unit,Oxford University Hospitals NHS Foundation Trust,University of Oxford,Oxford,United Kingdom
Scopus学科分类	Hepatology
TOP期刊	TOP期刊
引用统计	被引频次：175[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20883
专题	附属第一医院
通讯作者	Marjot, Thomas
作者单位	1.Oxford Liver Unit,Translational Gastroenterology Unit,Oxford University Hospitals NHS Foundation Trust,University of Oxford,Oxford,United Kingdom; 2.Division of Gastroenterology and Hepatology,University of North Carolina,NC,United States; 3.Centre for Statistics in Medicine,University of Oxford,Oxford,United Kingdom; 4.Tropical Medicine and Infectious diseases Department,Tanta University,Tanta,Egypt; 5.Department of Medicine,Section of Hepatology,Rush University Medical Center,Chicago,United States; 6.Liver Unit,Queen Elizabeth Hospital Birmingham,Birmingham,United Kingdom; 7.Liver Unit,Hospital Clínic,Barcelona,Spain,Institut d'Investigacions Biomèdiques,August Pi i Sunyer,Barcelona,Spain; 8.Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas,Barcelona,Spain; 9.Division of Pediatric Gastroenterology and Hepatology,University of North Carolina,Chapel Hill,United States; 10.Division of Gastroenterology/Hepatology,Department of Medicine,Beth Israel Deaconess Medical Center,Harvard Medical School,Boston,United States; 11.Division of Gastroenterology and Hepatology,Department of Medicine,Stanford University School of Medicine,Palo Alto,United States; 12.Shiraz Transplant Center,Abu-Ali Sina Hospital,Shiraz,Iran; 13.Department of Gastroenterology,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,Mexico City,Mexico; 14.Barts Liver Centre,Barts Health NHS Trust & Barts & The London School of Medicine & Dentistry,QMUL,London,United Kingdom; 15.Division of Digestive Health and Liver Diseases,Department of Medicine,University of Miami Miller School of Medicine,Miami,United States; 16.Sheila Sherlock Liver Unit,Royal Free Hospital,London,United Kingdom; 17.Department of Gastroenterology and Hepatology,Royal Liverpool Hospital,Liverpool University Hospitals NHS Foundation Trust,Liverpool,United Kingdom; 18.Cambridge Liver Unit,Addenbrooke's Hospital,Cambridge University Hospitals,Cambridge,United Kingdom; 19.Division of Liver Diseases,Department of Medicine,Icahn School of Medicine at Mount Sinai,New York,United States; 20.CHESS Center,Institute of Portal Hypertension,The First Hospital of Lanzhou University,Lanzhou,China; 21.Division of Gastroenterology,University of Washington,Seattle,United States; 22.Liver Center,Gastrointestinal Division,Massachusetts General Hospital,Harvard Medical School,Boston,United States; 23.Department of Gastroenterology & Hepatology,Changi General Hospital,Yong Loo Lin School of Medicine,National University of Singapore,Singapore; 24.MAFLD Research Center,Department of Hepatology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 25.Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease,Zhejiang Province,Wenzhou,China
推荐引用方式 GB/T 7714	Marjot, Thomas,Moon, Andrew M.,Cook, Jonathan A.,et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study[J]. JOURNAL OF HEPATOLOGY,2021,74(3):567-577.
APA	Marjot, Thomas., Moon, Andrew M.., Cook, Jonathan A.., Abd-Elsalam, Sherief., Aloman, Costica., ... & Webb, Gwilym J.. (2021). Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. JOURNAL OF HEPATOLOGY, 74(3), 567-577.
MLA	Marjot, Thomas,et al."Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study".JOURNAL OF HEPATOLOGY 74.3(2021):567-577.